Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/ard-2022-223044
Abstract: Only a minority of patients with eosinophilic granulomatosis with polyangiitis (EGPA) can be weaned-off glucocorticoids (GC) using conventional treatment strategies. The development of biological agents specifically inhibiting the IL-5 pathway provided the opportunity to treat… read more here.
Keywords: targeting interleukin; interleukin pathway; remission; egpa ... See more keywords
Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2018.00049
Abstract: Improved understanding of the contribution of eosinophils to various chronic inflammatory conditions, most notably allergic asthma, has encouraged development of monoclonal antibodies specifically targeting mediators and surface receptors involved in eosinophil expansion and activation. The… read more here.
Keywords: targeting interleukin; interleukin pathway; biology; pathway treatment ... See more keywords